Patents Examined by Benjamin P. Blumel
  • Patent number: 11905517
    Abstract: The invention relates to recombinant Kluyveromyces lactis (K. lactis) yeasts which are capable of the highly efficient expression of one or more foreign proteins and are suitable for use as a vaccine for generating a protective immune response against pathogens. The invention provides in particular K. lactis strains for the targeted cloning of foreign antigen-coding nucleic acids into the yeast genome of the K. lactis strain, which is characterized in that the K. lactis strain has integrated expression cassettes for foreign antigens as an alternative or in addition to the KILAC4 locus on the KIURA3-20 locus (KLLA0E22771g) and/or on the KIMET5-1 locus (KLLA0B03938g). The invention further relates to integrative expression vectors and to methods for producing the K. lactis strains of the invention as well as to the use thereof as vaccines.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: February 20, 2024
    Inventors: Hans Caspar Hührlimann, Martina Behrens, Mandy Gebauer, Karin Breunig, Sven-Erik Behrens
  • Patent number: 11904015
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 20, 2024
    Inventors: Frank Bedu-Addo, Eric Jacobson, Kenya Johnson
  • Patent number: 11896636
    Abstract: This invention generally relates to immunogenic compositions that comprise an RNA component and a polypeptide component. Immunogenic compositions that deliver antigens in two different forms—a first antigen from a pathogen, in RNA-coded form; and a second antigen from a different pathogen, in polypeptide form—are effective in inducing immune response to both pathogens.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: February 13, 2024
    Inventors: Andrew Geall, Ethan Settembre
  • Patent number: 11896665
    Abstract: An isolated protein comprises respective amino acid sequences of each of a plurality of CTL epitopes from two or more different herpesvirus antigens and further comprises an intervening amino acid or amino acid sequence between at least two of said CTL epitopes comprising proteasome liberation amino acids or amino acid sequences and, optionally, Transporter Associated with Antigen Processing recognition motifs. The isolated protein is capable of rapidly expanding human cytotoxic T lymphocytes (CTL) in vitro and eliciting a CTL immune response in vivo upon administration to an animal as an exogenous protein. Typically, the isolated protein comprises no more than twenty (20) CTL epitopes derived from cytomegalovirus and/or Epstein-Barr virus antigens.
    Type: Grant
    Filed: April 9, 2021
    Date of Patent: February 13, 2024
    Assignee: The Council of the Queensland Institute of Medical Research
    Inventors: Rajiv Khanna, Dasari Vijayendra
  • Patent number: 11897918
    Abstract: Disclosed herein are methods for increasing protein yield and cellular productivity. Chemical agents facilitate host cell production of biological molecules to increase product yield.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 13, 2024
    Assignee: Seqirus UK Limited
    Inventors: Samuel Ho, David Parker, Peter Fekkes, Ivna De Souza, Peter Mason, Pirada Allen
  • Patent number: 11891630
    Abstract: The present disclosure provides methods of generating recombinant bacteriophage genomes via semi-synthesis. Specifically, the present technology provides methods of integrating a heterologous nucleic acid sequence into a bacteriophage genome, and isolating recombinant bacteriophages that express the heterologous nucleic acid sequence.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: February 6, 2024
    Inventors: Kirsty A. McFarland, Miles T. Rogers, Connor McBrine, Jason W. Holder
  • Patent number: 11890338
    Abstract: An inactivated whole-virus influenza vaccine may have its antibody-inducing ability is maintained or enhanced and may cause fewer side reactions. A method for preparing an inactivated whole-virus influenza vaccine may use an embryonated chicken egg method, including subjecting a virus solution including a whole influenza virus collected from embryonated chicken eggs to a hypotonic treatment.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: February 6, 2024
    Inventors: Ryotaro Mitsumata, Shogo Misumi, Naoki Kishimoto, Takuma Gotanda, Nagisa Nakata
  • Patent number: 11883483
    Abstract: The present invention relates to a method of preparing an influenza working virus seed stock, a method of increasing infectivity of an influenza working virus seed stock, a method of preparing an influenza vaccine using the seed stock, an influenza vaccine prepared by the method, and an influenza working virus seed stock having increased infectivity.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: January 30, 2024
    Assignee: SK BIOSCIENCE CO., LTD.
    Inventors: Yun Hee Kim, Yong Wook Park, Dong Soo Ham, Hwan Ui Jung, Hun Kim
  • Patent number: 11879139
    Abstract: The present disclosure provides a scalable and cost-effective method of purifying recombinant viruses, such as recombinant lentiviruses. Also provided herein are recombinant viruses (e.g., lentiviruses) purified using the methods provided herein, which have a low level of impurities and high activity retention.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: January 23, 2024
    Inventors: Dichao Hu, Chuanzhen Pi, Kai Weng, Jinbo Guo, Hailong Liu, Yangzhou Wang, Weimeng Zhang, Jun Hua
  • Patent number: 11872215
    Abstract: Compounds, compositions, and methods are provided for covalently linking an antibody or an antibody fragment to a cargo molecule, such as a therapeutic or a diagnostic agent, using a combination of enzymatic glycan remodeling and click chemistry. The method allows a cargo molecule to be selectively and efficiently attached post-translationally to an antibody or an antibody fragment. Also provided are antibody drug conjugates, methods of making, and uses thereof.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: January 16, 2024
    Assignee: University of Georgia Research Foundation, Inc.
    Inventor: Geert-Jan Boons
  • Patent number: 11865084
    Abstract: The present invention relates to mRNAs suitable for use as mRNA-based vaccines against infections with MERS coronaviruses. Additionally, the present invention relates to a composition comprising the mRNAs and the use of the mRNAs or the composition for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of MERS coronavirus infections. The present invention further describes a method of treatment or prophylaxis of infections with MERS coronavirus using the mRNA sequences.
    Type: Grant
    Filed: September 7, 2021
    Date of Patent: January 9, 2024
    Assignee: CureVac SE
    Inventor: Susanne Rauch
  • Patent number: 11865172
    Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: January 9, 2024
    Inventors: Patti Cynthia Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
  • Patent number: 11857618
    Abstract: This disclosure relates to boosting the immunogenicity of vaccines using an adjuvant combination comprising a saponin and an agonist of the intracellular stimulator of interferon genes pathway. In certain embodiments, the vaccine comprises an inactivated virus, attenuated virus, virus protein, virus like particle, or virosome. In certain embodiments, the human subject is of advanced age or elderly. In certain embodiments, the viral vaccine is an influenza vaccine.
    Type: Grant
    Filed: April 16, 2021
    Date of Patent: January 2, 2024
    Assignee: Emory University
    Inventors: Richard Compans, Elena Vassilieva
  • Patent number: 11857621
    Abstract: A pDNA-based vaccine against SARS-CoV-2 and methods for preventing or treating COVID-19 using it. The pDNA-vaccine encodes an immunogenic portion of SARS-CoV S1 protein, such as that encoded by SEQ ID NO: 1 or a fragment thereof, and may be conveniently administered intramuscularly without the need for electroporation or use of a gene gun.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: January 2, 2024
    Assignee: Imam Abdulrahman Bin Faisal University
    Inventor: Iman Almansour
  • Patent number: 11840710
    Abstract: Provided herein are methods for the purification of recombinant adeno-associated virus (rAAV) vectors that can be used for gene transfer and specifically for gene therapy or vaccination. Recombinant AAV vectors of the invention are substantially free of in-process impurities, including production components such as cellular nucleic acids, cellular proteins, helper virus, and media components.
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: December 12, 2023
    Assignee: Genzyme Corporation
    Inventors: Paulene McLean Quigley Sheldon, Peter S. Gagnon, Gina Nichols, Barbara A. Thorne
  • Patent number: 11833199
    Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: December 5, 2023
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Surender Khurana
  • Patent number: 11827906
    Abstract: A recombinant adeno-associated virus (rAAV) vector comprising an AAVhu68 capsid produced in a production system comprising a nucleotide sequence of SEQ ID NO: 1, or a sequence at least 75% identical thereto which encodes SEQ ID NO:2. The AAVhu68 capsid comprises subpopulations of highly deamidated asparagine residues in asparagine-glycine pairs in the amino acid sequence of SEQ ID NO: 2. Also provided are compositions containing the rAAV and uses thereof. Additionally, rAAV having an engineered AAV capsid comprising at least one subpopulation of vp1 or vp2 proteins having a Val at amino acid position 157 with reference to the AAVhu68 vp1 numbering are provided.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: November 28, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Qiang Wang, April Tepe, Kevin Turner
  • Patent number: 11801296
    Abstract: Provided herein are details on the construction of a recombinant African Swine Fever Virus (ASFV) live attenuated vaccine for prevention of ASF caused by various strains of ASFV, such as the highly virulent Georgia 2007 isolate (“ASFV-G”). An exemplary vaccine comprises the ASFV-G?A137R modified virus, a recombinant ASFV-G modified by deleting a portion of the A137R ORF rendering the A137R gene nonfunctional.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: October 31, 2023
    Assignee: The United States of America, as represented by The Secretary of Agriculture
    Inventors: Douglas P. Gladue, Manuel V. Borca
  • Patent number: 11795477
    Abstract: This document relates to adenovirus vectors and methods and materials related to using adenovirus vectors. For example, viruses, nucleic acid molecules encoding viruses, cell lines containing viral vectors, and methods for using viruses to deliver nucleic acid to cells in vitro or in vivo are provided. Methods and materials for using adenovirus vectors to induce immune responses and to treat cancer also are provided.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: October 24, 2023
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Michael A. Barry, Eric Weaver
  • Patent number: 11780888
    Abstract: The disclosure relates to a polypeptide comprising, or consisting of, the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 or a sequence having at least 97%-100% sequence identity to one of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 9 for use as an immunogen for the purpose of eliciting an immune response in a subject susceptible to infection with a coronavirus. The disclosed polypeptide is further useful in reducing the severity of symptoms associated with a coronavirus infection. In addition to use in a protein-based vaccine, the polypeptide of the disclosure can be encoded by a nucleic acid/ribonucleic acid and used in a nucleic acid vaccine or viral vector vaccine.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: October 10, 2023
    Inventors: Arlene I. Ramsingh, Janice Pata